StockData

Altimmune vs Avalo Therapeutics

ALT and AVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALT and AVTX compare

Avalo Therapeutics is the larger company, worth 1.3 times as much as Altimmune ($395M against $303M).

Avalo Therapeutics scores higher on the StockData Score (8 against 4 for Altimmune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALTAVTX
Size and price
Market cap$303M$395M
Share price$1.56$7.37
Change, 1 year−61.6%−50.0%
Change, 5 years−85.0%−99.9%
Beta (5Y)1.872.19
Employees1323
StockData Score
Total score48 (better)
Valuation score11
Growth score00
Performance score11
Health score26 (better)
Dividend score00
Valuation
P/B0.6× (better)0.9×
FCF yield−25.2%–
Growth
Revenue growth, 5Y average−65.3%−61.2% (better)
Profitability
Return on equity−28.9% (better)−36.3%
Return on invested capital−90.4%–
Financial health
Debt / equity0.07 (better)0.00
Interest coverage−28.3×–
Current ratio26.78 (better)19.31
Altman Z-score1.704.52 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−36.3%–
Shareholder yield−36.3%0.00% (better)
Ownership
Held by institutions77.9%135%
Held by insiders0.56%0.71%
Insider net buying, 12 months$452K (better)−$8.3M
Superinvestors holding1–
Short interest, % of float21.8%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.